RxDoctor Payments Data

Laura Chin-Lenn, MD

Family Medicine · Boynton Beach, FLNPI 1619983624

Payments from drug & device makers

$1,188in general payments, 2019–2025

Across 57 payments — averaging $20.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$269
  • AstraZeneca$187
  • Novo Nordisk$131
  • Amarin Pharma, Inc.$121
  • Pfizer$91
  • Xeris Pharmaceuticals, Inc.$77
  • plus $313 from 9 others

What the payments were for

  • Food & beverage$1,182100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,188 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$40,774
Medicare patients
120
Services billed
837

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban122$104,685
FarxigaDapagliflozin Propanediol51$40,244
JardianceEmpagliflozin45$35,149
JanuviaSitagliptin Phosphate36$32,945
Trelegy ElliptaFluticasone/Umeclidin/Vilanter42$30,287
XareltoRivaroxaban19$26,230
MounjaroTirzepatide24$24,693
EntrestoSacubitril/Valsartan14$17,698
OzempicSemaglutide13$17,593
Breo ElliptaFluticasone/Vilanterol13$8,777
Albuterol Sulfate HfaAlbuterol Sulfate248$6,747
Tresiba Flextouch U-200Insulin Degludec12$5,957
Tresiba Flextouch U-100Insulin Degludec11$5,737
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$4,444
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$4,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$104,685122 claims
AstraZenecaFarxiga$187$40,24451 claims
GSKTrelegy Ellipta, Breo Ellipta$269$39,06355 claims
Johnson & JohnsonXarelto$20$26,23019 claims
Lilly USA, LLCMounjaro$60$24,69324 claims
NovartisEntresto$37$17,69814 claims
Novo NordiskOzempic$131$17,59313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Boynton Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →